Evidence map›Paper›PMID 40076364›Full record

ArticleMolecules (Basel, Switzerland)2025

Determination of Urolithin A in Health Products by Ultra-High-Performance Liquid Chromatography.

Yue E, Zhuang Wang, Jiahui Nie

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yue ESchool of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
Zhuang WangSchool of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.ORCID 0009-0003-5967-8342
Jiahui NieZhejiang Institute of Tianjin University, Shaoxing 312300, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study establishes and validates a novel ultra-high-performance liquid chromatography (UHPLC) method for the determination of urolithin A content in health products, a bioactive compound with potential anti-aging properties. Given the lack of standardized analytical methods for urolithin A in health products, this research addresses a critical gap in quality control. The method employs a methanol-water mobile phase, optimized gradient elution, and a specialized UPLC column (ACQUITY UPLC CSH Fluoro Phenyl) to achieve high resolution and specificity in the separation of urolithin A from its impurities. A variety of diluents, extraction solvents, and extraction times were tested to maximize analyte recovery and stability, with pure methanol yielding the highest recovery rate (over 95%) in 30 min. The method was validated in terms of linearity, sensitivity, repeatability, specificity, and precision. The calibration curve for urolithin A exhibited excellent linearity (r

Indexed as

CoumarinsChromatography, High Pressure LiquidReproducibility of Results3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneCoumarinshealth productsultra-high-performance liquid chromatography methodurolithin A

Identifiers

PMID40076364
PMCPMC11901897

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.